ContractAmarantus Bioscience Holdings, Inc. • April 21st, 2014 • Pharmaceutical preparations • New York
THIS NOTE HAS NOT (AND ANY SHARES OF STOCK ISSUABLE UPON THE TRIGGERING OF AN EVENT OF DEFAULT MAY NOT HAVE) BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. NEITHER THIS NOTE NOR ANY SHARES OF STOCK ISSUABLE UPON THE TRIGGERING OF AN EVENT OF DEFAULT MAY BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THIS NOTE OR SHARES OF STOCK ISSUABLE UPON DEFAULT UNDER THIS NOTE UNDER SUCH ACT UNLESS SUCH REGISTRATION IS NOT REQUIRED PURSUANT TO A VALID EXEMPTION THEREFROM UNDER THE ACT.
OPTION AGREEMENTOption Agreement • April 21st, 2014 • Amarantus Bioscience Holdings, Inc. • Pharmaceutical preparations • Florida
This Agreement, effective as of November __, 2013 (the “Effective Date”), is between the University of Miami (“University” or “Licensor”), and Amarantus BioScience Holdings, Inc., a Nevada company (“Company” or Licensee”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 21st, 2014 • Amarantus Bioscience Holdings, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement (the “Agreement”), effective as of December 12, 2013 (the “Effective Date”), is between the University of Massachusetts (“University”), a public institution of higher education of the Commonwealth of Massachusetts as represented by its Worcester campus, and Amarantus Bioscience Holdings, Inc. (“Company”), a California corporation.
OPTION AGREEMENTOption Agreement • April 21st, 2014 • Amarantus Bioscience Holdings, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of February 28, 2014 (the “Effective Date”), is between the University of Massachusetts (“University”), a public institution of higher education of the Commonwealth of Massachusetts, as represented by its Amherst campus, and Amarantus Bioscience Holdings, Inc. (“Company”), a Nevada corporation.
